Detalhe da pesquisa
1.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
N Engl J Med
; 2024 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38828951
2.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38832972
3.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
4.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38828933
5.
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Blood
; 141(6): 579-591, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130300
6.
Genetic justification of COVID-19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm.
J Cell Mol Med
; 28(4): e18105, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38339761
7.
Thrombotic and bleeding complications in patients with AL amyloidosis.
Br J Haematol
; 204(5): 1816-1824, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38321638
8.
Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRFHisGTG results in patients' poor treatment outcome.
Br J Haematol
; 204(5): 1790-1800, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38414235
9.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
10.
Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin.
Basic Res Cardiol
; 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38520533
11.
How I treat relapsed multiple myeloma.
Blood
; 139(19): 2904-2917, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007326
12.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269818
13.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289038
14.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385280
15.
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356458
16.
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Haematologica
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426292
17.
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299578
18.
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.
BMC Cancer
; 24(1): 541, 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38684948
19.
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.
Eur J Haematol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38693052
20.
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Am J Hematol
; 99(3): 396-407, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38298023